Extract from the Register of European Patents

EP About this file: EP1459750

EP1459750 - (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.04.2006
Database last updated on 01.04.2026
Most recent event   Tooltip22.01.2016Change - lapse in a contracting statepublished on 24.02.2016  [2016/08]
Applicant(s)For all designated states
Pharmacia & Upjohn Company LLC
301 Henrietta Street
Kalamazoo, MI 49001 / US
[2005/22]
Former [2004/39]For all designated states
Pharmacia & Upjohn Company
301 Henrietta Street
Kalamazoo, MI 49007 / US
Inventor(s)01 / Ahmed, Saeeduddin
9889 Defoe Court
Portage Michigan 49002 / US
02 / Birgerson, Lars
54 Hillcrest Road
Martinsville New Jersey 08836 / US
03 / Cetera, Pasquale
5 Pine Place
Annandale New Jersey 08801 / US
04 / Marshall, Robert Clyde
7560 Fieldwood Circle
Mattawan Michigan 49071 / US
05 / McArthur, Robert
531 Carrington Court
Kalamazoo Michigan 49009 / US
06 / Taylor, Duncan P.
8722 West F. Avenue
Kalamazoo Michigan 49009 / US
07 / Wong, Erik H.F.
7352 Hampstead Lane
Portage Michigan 49024 / US
 [2004/39]
Representative(s)Duncan, Garreth Andrew
Pfizer Limited
UK Patent Department
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
[N/P]
Former [2004/39]Duncan, Garreth Andrew
Pfizer Limited, UK Patent Department, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date04013382.922.06.2000
[2004/39]
Priority number, dateUS19990141968P01.07.1999         Original published format: US 141968 P
US19990144131P16.07.1999         Original published format: US 144131 P
US19990158256P06.10.1999         Original published format: US 158256 P
US19990170381P13.12.1999         Original published format: US 170381 P
[2004/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1459750
Date:22.09.2004
Language:EN
[2004/39]
Type: B1 Patent specification 
No.:EP1459750
Date:01.06.2005
Language:EN
[2005/22]
Search report(s)(Supplementary) European search report - dispatched on:EP04.08.2004
ClassificationIPC:A61K31/5375, A61P29/00, A61P25/00
[2004/39]
CPC:
A61K31/5375 (EP); A61P13/00 (EP); A61P21/00 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P25/06 (EP);
A61P25/22 (EP); A61P25/24 (EP); A61P29/00 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2004/39]
Extension statesAL07.06.2004
LT07.06.2004
LV07.06.2004
MK07.06.2004
RO07.06.2004
SI07.06.2004
TitleGerman:(S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen[2004/39]
English:(S,S)-reboxetine for treating fibromyalgia and other somatoform disorders[2004/39]
French:(S,S)-réboxétine pour traiter les fibromyalgies et d'autres troubles somatoformes[2004/39]
Examination procedure07.06.2004Examination requested  [2004/39]
01.11.2004Amendment by applicant (claims and/or description)
21.01.2005Communication of intention to grant the patent
29.03.2005Fee for grant paid
29.03.2005Fee for publishing/printing paid
Parent application(s)   TooltipEP00941659.5  / EP1196172
Opposition(s)02.03.2006No opposition filed within time limit [2006/21]
Fees paidRenewal fee
07.06.2004Renewal fee patent year 03
07.06.2004Renewal fee patent year 04
07.06.2004Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Former [2007/34]IT22.06.2005
Documents cited:Search[E] WO0162236  (UPJOHN CO et al.) [E] 1-9 * abstract * * page 6, line 28 - page 7, line 7; claims 1,3,7,8 *
 [E] WO0147503  (PHARMACIA AB et al.) [E] 1-9 * abstract * * page 3, line 5 - line 32 * * page 4, line 23 - page 5, line 2; examples 17,18; claims 1,4,7,20,23 *
 [PX] WO0000120  (PRAECIS PHARM INC et al.) [PX] 1-9 * abstract * * page 4, line 22 - line 29 * * page 6, line 15 - line 21; example 34; claims 1,4 *
 [DA] GB2167407  (ERBA FARMITALIA et al.) [DA] 1-9 * abstract * * page 4, line 50 - page 5, line 25; examples 11-13; claim - *
 [A]   FRIGERIO E ET AL: "PHARMACOKINETICS OF REBOXETINE ENANTIOMERS IN THE DOG", CHIRALITY, WILEY-LISS, NEW YORK, US, vol. 9, 1997, pages 303 - 306, XP000991008, ISSN: 0899-0042 [A] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1520-636X(1997)9:3<303::AID-CHIR17>3.0.CO;2-R
 [A]   DOSTERT P ET AL: "REVIEW OF THE PHARMACOKINETICS AND METABOLISM OF REBOXETINE, A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 7, no. SUPPL 1, 1997, pages S23 - S35, XP000989913, ISSN: 0924-977X [A] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0924-977X(97)00417-3
 [A]   BURROWS G D ET AL: "ANTIDEPRESSANT EFFICACY AND TOLERABILITY OF THE SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR REBOXETINE: A REVIEW", JOURNAL OF CLINICAL PSYCHIATRY, XX, XX, vol. 59, no. SUPPL 14, 1998, pages 4 - 7, XP000989995, ISSN: 0160-6689 [A] 1-9 * the whole document *
 [A]   ANONYMOUS: "REBOXETINE - ANOTHER NEW ANTIDEPRESSANT", DRUG AND THERAPEUTICS BULLETIN, CONSUMERS ASSOCIATION, LONDON, GB, vol. 36, no. 11, November 1998 (1998-11-01), pages 86 - 88, XP001011361, ISSN: 0012-6543 [A] 1-9 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.